Alternative Data for Scilex Holding
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 76 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Employee Rating | 62 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 58 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,028 | Sign up | Sign up | Sign up |
| X Mentions | 5 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 40 | Sign up | Sign up | Sign up |
| Linkedin Employees | 68 | Sign up | Sign up | Sign up |
About Scilex Holding
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain.
| Price | $8.81 |
| Target Price | Sign up |
| Volume | 16,859 |
| Market Cap | $61M |
| Year Range | $6.25 - $30 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Drug Manufacturers |
In the news
 |
Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend PaymentsJanuary 6 - Yahoo |
Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property CounselJanuary 2 - GlobeNewswire |
|
|
Trending tickers: Datavault, Novo Nordisk, FedEx, SBI and NatWestFebruary 8 - Yahoo |
Chronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics | DelveInsightJanuary 28 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 11M | 3.3M | 7.2M | -257M | -254M | -22.170 |
| Q2 '25 | 9.9M | 3.3M | 6.6M | -86M | -40M | -7.420 |
| Q1 '25 | 5M | 1.4M | 3.6M | -26M | -23M | -2.260 |
| Q4 '24 | 15M | 4.7M | 10M | -6.5M | -5.2M | -2.980 |
| Q3 '24 | 14M | 3.8M | 11M | -4.4M | 0 | -1.365 |
Insider Transactions View All
| Scilex Holding Co filed to sell 244,445,260 shares at $0.5. December 30 '25 |
| Scilex Holding Co filed to sell 254,102,560 shares at $0.7. December 30 '25 |
| Scilex Holding Co filed to sell 261,413,544 shares at $0.8. December 30 '25 |
| SHAH JAISIM filed to buy 139,333 shares at $0.5. December 18 '24 |
| Ji Henry filed to buy 320,161 shares at $0.9. October 31 '24 |
Similar companies
Read more about Scilex Holding (SCLX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Scilex Holding
The Market Cap of Scilex Holding is $61M.
Currently, the price of one share of Scilex Holding stock is $8.81.
The SCLX stock price chart above provides a comprehensive visual representation of Scilex Holding's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Scilex Holding shares. Our platform offers an up-to-date SCLX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Scilex Holding (SCLX) does not offer dividends to its shareholders. Investors interested in Scilex Holding should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Scilex Holding are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
